Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7211-7219

  Plewe, Michael B ^a   Butler, Scott L ^b   Dress, Klaus R ^a   Hu, Qiyue ^a   Johnson, Ted W ^a   Kuehler, Jon E ^a,d   Kuki, Atsuo ^a   Lam, Hieu ^a   Liu, Wen ^a,c   Nowlin, Dawn ^a   Peng, Qinghai ^a   Rahavendran, Sadayappan V ^a   Tanis, Steven P ^a   Tran, Khanh T ^a   Wang, Hai ^a   Yang, Anle ^a   Zhang, Junhu ^a,e  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c GENENTECH INC   (United States)

^d Ampac Fine Chemicals   (United States)

^e Trius Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2,4 DIFLUOROBENZYL) N METHYL N METHOXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (2 CARBAMOYL 4 FLUOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (2 CYANO 4 FLUOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (2,3 DICHLOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (2,4 DIFLUOROBENZYL) N HYDROXY 1H PYRROLO(2,3 C)PYRIDINE 5 CARBOXAMIDE; 1 (2,4 DIFLUOROBENZYL) N HYDROXY N METHYL 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (2,4 DIFLUOROBENZYL) N METHOXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (3 CARBAMOYL 4 FLUOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (3 CARBAMOYLBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (3 CHLORO 2 FLUOROBENZYL) N HYDROXY 1H PYRROLO(2,3 C)PYRIDINE 5 CARBOXAMIDE; 1 (3 CHLORO 2,6 DIFLUOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (3 CYANOBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 CARBAMOYLBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 CYANOBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY 1H PYRROLO(2,3 C)PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY N (3 HYDROXYPROPYL) 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY N ISOBUTYL 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY N ISOPROPYL 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY N METHYL 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (4 FLUOROBENZYL) N HYDROXY N PROPYL 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; 1 (5 CHLOROTHIOPHEN 2 YLMETHYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBOXYLIC ACID DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; INTEGRASE INHIBITOR; N BENZYL 1 (4 FLUOROBENZYL) N HYDROXY 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N HYDROXY 1 (PYRIDIN 2 YLMETHYL) 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; N HYDROXY 1 [[6 (HYDROXYMETHYL)PYRIDIN 2 YL]METHYL] 1H PYRROLO[2,3 C]PYRIDINE 5 CARBOXAMIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DRUG SYNTHESIS; GENOME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; VIRUS REPLICATION;

EID: 70949102509     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900862n     Document Type: Article

References (40)

1. Castro, H. C.; Loreiro, N. I. V.; Pujol-Luz, M.; Souza, A. M. T.; Aluquerque, M. G.; Santos, D. O.; Cabral, L. M.; Frugulhetti, I. C; Rodrigues, C. R. HIV Reverse Transcriptase: A Therapeutic Target in the Spotlight. Curr. Med. Chem. 2006, 12, 313-424.
2. Mastrolorenzo, A.; Rusconi, S.; Scozzafava, A.; Supuran, C. Inhibitors of HIV-1 Protease. 10 Years after. Expert Opin. Ther. Pat. 2006, 16, 1067-1091.
3. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, R. C.; Napier, C.; Webster, R.; Armour, A.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother. 2005, 49, 4721-4732
4. Roy, M.; Gulick, R. M.; Lalezari, J.; Goodrich, J.; Clumeck, N.; DeJesus, E.; Andrzej Horban, A.; Nadler, J.; Clotet, B.; Karlsson, A.; Wohlfeiler, M.; Montana, J. B.; McHale, M.; Sullivan, J.; Ridgway, C.; Felstead, S.; Dunne, M. W.; van der Ryst, E.; Mayer, H. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. N. Engl. J. Med. 2008, 359, 1429-1441
5. Al-Mawsawi, L. Q.; Al-Safi, R. I; Neamati, N. Anti-Infectives: Clinical progress of HIV-1 Integrase Inhibitors. Expert Opin. Emerg. Drugs 2008, 13, 213-225
6. Pace, P.; Rowley, M. Integrase inhibitors for the Treatment of HIV Infection. Curr. Opin. Drug Discovery Dev. 2008, 11, 471-479.
7. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C.; Paz, O. G.; Hazuda, D. J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Marc, V.; Witmer, M. V.; Rowley, M. Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection. J. Med. Chem. 2008, 51, 5843-5855.
8. Anker, M.; Corales, R. B. Raltegravir (MK-0518): A Novel Integrase Inhibitor for the Treatment of HIV Infection. Expert Opin. Investig. Drugs 2008, 17, 97-103.
9. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Masao Matsuoka, M. Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 2008, 82, 764-774.
10. Serrao, E.; Odde, S.; Ramkumar, K.; Neamati, N. Raltegravir, Elvitegravir, and Metoogravir: The Birth of Me-Too HIV Integrase Inhibitors. Retrovirology 2009, 6, 25-39.
11. Hazuda, D. J.; Felock, P. J.; Hastings, J. C.; Pramanik, B.; Wolfe, A. L. Different Divalent Cations Requirements Uncouple the Assembly and Catalytic Reactions of Human Immunodeficiency Virus Type 1 Integrase. J. Virol. 1997, 71, 7005-7011.
12. Konsavage, W. M., Jr.; Sudol, M.; Katzman, M. Effects of Varying the Spacing within the DD-35-E Motif in the Catalytic Region of Retroviral Integrase. Virology 2008, 379, 223-233.
13. Bacchi, A.; Biemmi, M.; Carcelli, M.; Carta, F.; Compari, C.; Fisicaro, E.; Rogolino, D.; Sechi, M.; Sippel, M.; Sotriffer, C. A.; Sanchez, T. W.; Nouri Neamati, N. From Ligand to Complexes. Part 2. Remarks on Human Immunodeficiency Virus Type 1 Integrase Inhibition by β-Diketo Acid Metal Complexes. J. Med. Chem. 2008, 51, 7253-7264.
14. Sechui, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Deruda, M.; Al-Mawsawi, L. Q.; Neamati, N. From Ligand to Complexes: Inhibition of Human Immunodeficiency Virus Type I Integrase by Beta-Diketo Acid Metal Complexes. J. Med. Chem. 2006, 49, 4248-4260.
15. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand Efficiency: A Useful Metric for Lead Selection. Drug Discovery Today 2004, 9, 430-431.
16. Kuntz, I. D.; Chen, K.; Sharo, K. A.; Kollman, P. A. The Maximal Affinity of Ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002.
17. Kurzak, B; Kozalowski; Farkas, E. Hydroxamic and Aminohydroxamic Acids and their Complexes with Metal Ions. Coord. Chem. Rev. 1992, 114, 169-200.
18. Deloume, J. P.; Loiseleur, H.; Thomas, G. Structure du Picolate de Magnesium, Dihydraté. Acta Crystallogr., Sect. B: Struct. Sci. 1973, 29, 668-673.
19. Sahrif, M. A.; Aghabozorg, H.; Motyeian, E.; Ghadermazi, M.; Gharamaleki, J. A. Diaquabis (pyridine-2-carboxylato)magnesium(II) 0.15 hydrate. Acta Crystallogr., Sect. E: Struct. Rep. Online 2007, 63, 2235-2236.
20. Seda, S. H; Janczak, J.; Lisowski, J. Synthesis and Reactivity of Copper (II) Metallocrowns with (S)-Phenylalanine and 2-Picolinehydroxamic Acids. Inorg. Chim. Acta 2006, 359, 1055-1063.
21. Skipper, P. L.; Tannenbaum, S. R.; Thilly, W. G.; Furth, E. E.; Bishop, W. W. Mutagenicity of Hydroxamic Acids and Probable Involvement of Carbamoylation. Cancer Res. 1980, 40, 4704-4708.
22. Lee, M.-S.; Izobe, M.; Imaida, K.; Wang, C. Y.; Aoki, K. Carcinogenic Potential and Metabolic Activation of 2-Naphthohydroxamic acid in S. typhimurium TA91. Progr. Pharm. Clin. Pharm. 1991, 8, 275-288.
23. Lipczynska-Kochany, E.; Iwamua, H.; Takahashi, K.; Hakura, A.; Kawazoe, Y. Mutagenicity of Pyridine- and Quinoline-Carbohydroxamic Acid Derivatives. Mutat. Res. 1984, 135, 139-148.
24. Wang, C. Y.; Linsmaier-Bednar, E. M.; Lee, M.-S. Mutagenicity of the O-Esters of N-Acylhydroxyylamines for Salmonella. Chem. - Biol. Interact. 1981, 34, 267-278.
25. Bauer, L.; Exner, O. The Chemistry of Hydroxamic Acids and N-Hydroxyimides. Angew. Chem. 1974, 86, 419-458.
26. Angew. Chem., Int. Ed. Engl. 1974, 13, 376-384.
27. Aubrecht, J.; Osowski, J. J.; Persaud, P.; Cheung, J. R.; Ackerman, J.; Lopes, S. H.; Ku, W. W. Bioluminescent Salmonella Reverse Mutation Assay: A Screen for Detecting Mutagenicity with High Throughput Attributes. Mutagenesis 2007, 225, 335-342.
28. Dalvie, D.; Cosker, T.; Boyden, T.; Zhou, S.; Schroeder, C.; Potchoiba, M. J. Metabolism, Distribution and Excretion of a Matrix Metalloproteinase-13 Inhibitor, 4[4-(4-fluorophenoxy) benzenesulfonylamine]tetrahydropyran-4- carboxylic Acid Hydroxamide (CP-54443), in Rats and Dogs: Assessment of the Metabolic Profile of CP-544439 in Plasma and Urine of Humans. Drug Metab. Dispos. 2008, 36, 1869-1883.
29. Kim, H. M.; OH, S. J.; Park, S.-K.; Han, G.; Kim, K.; Lee, K. S.; Kang, J. S.; Nam, M.; Lee, K. In Vitro Metabolism of KBH-A40, a Novel δ-Lactam-based Histone Deacetylase (HDAC) Inhibitor, in Human Liver Microsomes and Serum. Xenobiotica 2008, 38, 282-293.
30. Tschaen, D. M.; Desmond, R.; King, A. O.; Fortin, M. C.; Pipik, B.; King, S.; Verhoeven, T. R. An Improved Procedure for Aromatic Cyanation. Synth. Commun. 1994, 24, 887-890
31. Batcho, A. D.; Leimgruber, W. Indoles from 2-Methylnitrobenzenes by Condensation with Formamide Acetales followed by Reduction: 4-Benzyloxyindole. Org. Synth. 1985, 63, 214-220.
32. Org. Synth. Coll. Vol.1990; 7, 34-40.
33. Prokopov, A. A.; Yakhontov, L. N. Synthesis of 6-Azaindole. Khim. Geterotsikl. Soedin. 1977, 1135-1136
34. Dekhane, M; Potier, P.; Dodd, R. H. A Practical Synthesis of 1H-pyrrolo[2,3-c]pyridine-5-Carboxylic Acid Derivatives from Pyrrolo-2-Carboxaldehydes. Tetrahedron 1993, 49, 8139-8146.
35. Hauser, C. R.; Renfrow, W. B., Jr. Benzohydroxamic Acid. Org. Synth. 1939, 19, 15-16.
36. Org. Synth. Coll. Vol.1943, 2, 67-68.
37. Doleschall, G. An Efficient Synthesis of N-Alkylated Hydroxylamines. Tetrahedron Lett. 1987, 28, 2993-2994.
38. Hu, Q.; Kuki, A.; Nowlin, D. M.; Plewe, M. B.; Wang, H.; Zhang, J. HIV Integrase Inhibitors, Pharmaceutical Compositions and Methods for their Use. U.S. Patent US 7,368,571, May 6, 2008.
39. Chen, C-H. J.; Krucinsci, J.; Miercke, L. J. W.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M. Crystal Structure of the HIV-1 Integrase Catalytic Core and C-terminal Domain: a Model for Viral DNA Binding. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8233-8238.
40. Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural products for AIDS-Antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.